Group 1 - The core point of the article is that JingTai Holdings (02228) has seen a significant stock price increase following its inclusion in the FTSE China Small Cap Index, indicating greater capital attention and liquidity premium [1][1] - As of the report, JingTai Holdings' stock rose over 5%, trading at 11.03 HKD with a transaction volume of 1.487 billion HKD [1][1] - The inclusion in the FTSE index became effective after the market close on September 19, which is expected to enhance the company's visibility and attract more investors [1][1] Group 2 - According to招商证券, JingTai Technology's AI pharmaceutical business is progressing steadily, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1][1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1][1] - JingTai has signed a pipeline cooperation agreement with DoveTree, with a total order scale of 5.99 billion USD, receiving an initial payment of 51 million USD, which is expected to contribute positively to its performance [1][1] - The company has successfully expanded its technology platform into various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physics computing, multimodal AI, and automation platforms [1][1]

Group 1 - The core point of the article highlights that Crystal Tech Holdings (02228) saw a significant stock price increase, rising over 5% and reaching HKD 11.03, with a trading volume of HKD 1.487 billion [1] - Crystal Tech Holdings has been included in the FTSE China Small Cap Index as part of the FTSE Russell Index Company's semi-annual adjustments, effective after the market close on September 19 [1] - Inclusion in an international index indicates broader capital attention and liquidity premium for the company [1] Group 2 - According to招商证券, Crystal Tech's AI pharmaceutical business is steadily advancing towards commercialization, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - Crystal Tech has signed a pipeline cooperation agreement with DoveTree, with a total order scale of USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] Group 3 - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physical computing, multimodal AI, and automation platforms [1]